Search Result

Pathways Recommended:	TGF-beta/Smad

Results for "

beta blocker

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (5) Amyloid-β (9) Beta-secretase (1) Dopamine β-hydroxylase (1) TGF-beta/Smad (14) TGF-β Receptor (5) β-catenin (7) 5-HT Receptor (7) Adrenergic Receptor (114) Amino Acid Derivatives (1) Anaplastic lymphoma kinase (ALK) (2) Angiotensin Receptor (2) Antibiotic (6) Apoptosis (17) Arrestin (5) Aryl Hydrocarbon Receptor (1) Autophagy (20) Bacterial (11) Bcr-Abl (1) Biochemical Assay Reagents (2) c-Fms (1) c-Kit (1) c-Myc (1) Calcium Channel (12) Casein Kinase (4) Caspase (1) Cathepsin (1) CDK (4) Chloride Channel (2) Cholinesterase (ChE) (1) COX (3) CXCR (2) Cytochrome P450 (4) Dipeptidyl Peptidase (1) DNA/RNA Synthesis (9) Drug Metabolite (6) E1/E2/E3 Enzyme (1) EGFR (1) Endogenous Metabolite (6) ERK (4) Estrogen Receptor/ERR (1) Ferroportin (1) Ferroptosis (3) FLT3 (1) GABA Receptor (2) Glucosidase (1) GnRH Receptor (1) GSK-3 (1) Histamine Receptor (1) HSP (2) IAP (1) IKK (6) Integrin (9) Interleukin Related (2) Isotope-Labeled Compounds (17) Lipoxygenase (2) mAChR (3) MARCKS (1) Mitophagy (3) MMP (1) mTOR (2) nAChR (10) NF-κB (7) NOD-like Receptor (NLR) (3) Opioid Receptor (1) P2X Receptor (4) p38 MAPK (4) Parasite (10) PDGFR (4) PDK-1 (1) Phosphatase (1) Phosphodiesterase (PDE) (1) Phospholipase (1) PI3K (5) PKA (1) PKC (1) Potassium Channel (15) Prolyl Endopeptidase (PREP) (1) RAR/RXR (1) Reactive Oxygen Species (1) ROCK (1) SARS-CoV (3) Sodium Channel (14) TAM Receptor (1) Tau Protein (1) Thyroid Hormone Receptor (2) TNF Receptor (1) Toll-like Receptor (TLR) (1) TRP Channel (1) Tyrosinase (1) VEGFR (2) Wnt (5)
By Research Areas:	Cancer (89) Cardiovascular Disease (123) Endocrinology (55) Infection (16) Inflammation/Immunology (60) Metabolic Disease (12) Neurological Disease (53)

By Targets:

11β-HSD (5)

Amyloid-β (9)

Beta-secretase (1)

Dopamine β-hydroxylase (1)

TGF-beta/Smad (14)

TGF-β Receptor (5)

β-catenin (7)

5-HT Receptor (7)

Adrenergic Receptor (114)

Amino Acid Derivatives (1)

Anaplastic lymphoma kinase (ALK) (2)

Angiotensin Receptor (2)

Antibiotic (6)

Apoptosis (17)

Arrestin (5)

Aryl Hydrocarbon Receptor (1)

Autophagy (20)

Bacterial (11)

Bcr-Abl (1)

Biochemical Assay Reagents (2)

c-Fms (1)

c-Kit (1)

c-Myc (1)

Calcium Channel (12)

Casein Kinase (4)

Caspase (1)

Cathepsin (1)

CDK (4)

Chloride Channel (2)

Cholinesterase (ChE) (1)

COX (3)

CXCR (2)

Cytochrome P450 (4)

Dipeptidyl Peptidase (1)

DNA/RNA Synthesis (9)

Drug Metabolite (6)

E1/E2/E3 Enzyme (1)

EGFR (1)

Endogenous Metabolite (6)

ERK (4)

Estrogen Receptor/ERR (1)

Ferroportin (1)

Ferroptosis (3)

FLT3 (1)

GABA Receptor (2)

Glucosidase (1)

GnRH Receptor (1)

GSK-3 (1)

Histamine Receptor (1)

HSP (2)

IAP (1)

IKK (6)

Integrin (9)

Interleukin Related (2)

Isotope-Labeled Compounds (17)

Lipoxygenase (2)

mAChR (3)

MARCKS (1)

Mitophagy (3)

MMP (1)

mTOR (2)

nAChR (10)

NF-κB (7)

NOD-like Receptor (NLR) (3)

Opioid Receptor (1)

P2X Receptor (4)

p38 MAPK (4)

Parasite (10)

PDGFR (4)

PDK-1 (1)

Phosphatase (1)

Phosphodiesterase (PDE) (1)

Phospholipase (1)

PI3K (5)

PKA (1)

PKC (1)

Potassium Channel (15)

Prolyl Endopeptidase (PREP) (1)

RAR/RXR (1)

Reactive Oxygen Species (1)

ROCK (1)

SARS-CoV (3)

Sodium Channel (14)

TAM Receptor (1)

Tau Protein (1)

Thyroid Hormone Receptor (2)

TNF Receptor (1)

Toll-like Receptor (TLR) (1)

TRP Channel (1)

Tyrosinase (1)

VEGFR (2)

Wnt (5)

By Research Areas:

Cancer (89)

Cardiovascular Disease (123)

Endocrinology (55)

Infection (16)

Inflammation/Immunology (60)

Metabolic Disease (12)

Neurological Disease (53)

285

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Amyloid-β TGF-β Receptor Beta-secretase β-glucuronidase TGF-beta/Smad 17β-HSD β-catenin 11β-HSD Beta-lactamase Dopamine β-hydroxylase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0203A

Nebivolol hydrochloride 3 Publications Verification R 065824 hydrochloride	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .

HY-B0432

Propafenone 1 Publications Verification SA-79	Sodium Channel Adrenergic Receptor Potassium Channel	Cardiovascular Disease Cancer
Propafenone (SA-79), a sodium-channel blocker, acts an antiarrhythmic agent. Propafenone also has high affinity for the β receptor (IC₅₀=32 nM) . Propafenone blocks the transient outward current (Ito) and the sustained delayed rectifier K current (Isus) with IC₅₀ values of 4.9 μm and 8.6 μm, respectively . Propafenone suppresses esophageal cancer proliferation through inducing mitochondrial dysfunction and induce apoptosis .

HY-B1392

Esmolol hydrochloride 3 Publications Verification	Adrenergic Receptor Autophagy Mitophagy	Cardiovascular Disease Endocrinology Cancer
Esmolol hydrochloride is a beta adrenergic receptor blocker.

HY-B0381B

Levobetaxolol hydrochloride (S)-betaxolol hydrochloride; AL-1577A	Adrenergic Receptor	Neurological Disease Endocrinology
Levobetaxolol hydrochloride is a beta-adrenergic receptor inhibitor (beta blocker) that can lower the pressure in the eye.

HY-B0203

Nebivolol R 065824	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Nebivolol (R 065824) is an orally active beta receptor blocker and has the high beta(1)-receptor affinity. Nebivolol has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .

HY-B0432R

Propafenone (Standard)	Sodium Channel Adrenergic Receptor Potassium Channel	Cardiovascular Disease Cancer
Propafenone (Standard) is the analytical standard of Propafenone. This product is intended for research and analytical applications. Propafenone (SA-79), a sodium-channel blocker, acts an antiarrhythmic agent. Propafenone also has high affinity for the β receptor (IC₅₀=32 nM) . Propafenone blocks the transient outward current (Ito) and the sustained delayed rectifier K current (Isus) with IC₅₀ values of 4.9 μm and 8.6 μm, respectively . Propafenone suppresses esophageal cancer proliferation through inducing mitochondrial dysfunction and induce apoptosis .

HY-141468

β-Chlornaltrexamine dihydrochloride β-CNA dihydrochloride	Opioid Receptor	Neurological Disease
β-Chlornaltrexamine dihydrochloride (β-CNA dihydrochloride) is a potent long-term opioid receptor blocker. β-Chlornaltrexamine dihydrochloride can effectively block the inhibitory effect of κ opioid receptor agonists on dopamine release. β-Chlornaltrexamine dihydrochloride can be used to study the mechanism of pain perception .

HY-12767

Carvedilol metabolite 4-Hydroxyphenyl Carvedilol 4-Hydroxyphenyl Carvedilol; 4-Hydroxycarvedilol	Drug Metabolite	Cardiovascular Disease Inflammation/Immunology Cancer
4-Hydroxyphenyl Carvedilol is a metabolite of Carvedilol, which is a nonselective beta blocker/alpha-1 blocker.

HY-101752

(±)-Befunolol	Adrenergic Receptor	Cardiovascular Disease Endocrinology
(±)-Befunolol is a *β-adrenoceptor* blocking agent.

HY-U00016

Teoprolol	Adrenergic Receptor	Endocrinology
Teoprolol is a β-adrenergic receptor blocker.

HY-100141

Ancarolol	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Ancarolol is a *beta-adrenergic* blocking agent.

HY-101752A

(±)-Befunolol hydrochloride	Adrenergic Receptor	Cardiovascular Disease Endocrinology
(±)-Befunolol hydrochloride is a *β-adrenoceptor* blocking agent.

HY-B1392S

Esmolol-d7 hydrochloride	Adrenergic Receptor Autophagy Mitophagy	Cardiovascular Disease Endocrinology
Esmolol-d₇ (hydrochloride) is the deuterium labeled Esmolol hydrochloride. Esmolol hydrochloride is a beta adrenergic receptor blocker[1][2].

HY-127010

Arnolol	Adrenergic Receptor	Cardiovascular Disease
Arnolol is a beta blocker with a pressure-lowering action .

HY-101434A

Cetamolol hydrochloride AI-27303 hydrochloride; ICI-72222 hydrochloride	Others	Others
Cetamolol hydrochloride is classified as a potent β1-blocker with intrinsic sympathomimetic activity and cardioselectivity. Low and medium doses of Cetamolol and Atenolol produce a more prolonged inhibitory effect than the same doses of Propranolol and Dexpropranolol.

HY-16316

Metipranolol hydrochloride 1 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Metipranolol hydrochloride is a non-selective β adrenergic receptor blocking agent.

HY-121692

(S)-Alprenolol	Adrenergic Receptor	Cardiovascular Disease
(S)-Alprenolol is a potent and nonselective *β-blocker* .

HY-121692B

(S)-Alprenolol hydrochloride	Adrenergic Receptor	Cardiovascular Disease
(S)-Alprenolol hydrochloride is a potent and nonselective *β-blocker* .

HY-B1154

Penbutolol sulfate 1 Publications Verification (-)-Terbuclomine	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Penbutolol sulfate is able to bind to both beta-1 adrenergic receptors and beta-2 adrenergic receptors (the two subtypes), thus making it a non-selective β blocker.

HY-121843

Ronactolol	Adrenergic Receptor	Endocrinology
Ronactolol, an aminopropanol derivative with β-adrenoceptor blocking activity .

HY-N2922

β-Amyrin	Amyloid-β	Neurological Disease
β-Amyrin, an ingredient of Celastrus hindsii, blocks amyloid β (Aβ)-induced long-term potentiation (LTP) impairment. β-amyrin is a promising candidate of treatment for AD .

HY-B0804S

Nadolol-d9 SQ-11725-d₉	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Nadolol-d₉ is the deuterium labeled Nadolol. Nadolol is a non-selective and orally active β-adrenergic receptors blocker[1].

HY-103196

Sotalol	Adrenergic Receptor Potassium Channel	Cardiovascular Disease Neurological Disease
Sotalol is an orally active, non-selective β-adrenergic receptor blocker. Sotalol is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent .

HY-U00386

Bometolol Hydrochloride	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Bometolol Hydrochloride is a *beta-adrenergic* blocking agent, used for the research of cardiovascular disease.

HY-W096097

Butofilolol	Adrenergic Receptor	Cardiovascular Disease
Butofilolol is a potent *β-blocking* agent used in the research of hypertension .

HY-103214

Bucindolol	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Bucindolol is a β1-adrenergic receptor blocker, with intrinsic sympathomimetic activity, used in the research of heart failure .

HY-B0437

Sotalol hydrochloride 2 Publications Verification MJ 1999	Adrenergic Receptor Potassium Channel	Cardiovascular Disease Neurological Disease
Sotalol hydrochloride (MJ 1999) is an orally active, non-selective β-adrenergic receptor blocker. Sotalol hydrochloride is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol hydrochloride blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent .

HY-101804

(E)-Alprenoxime CDDD-1815	Others	Cardiovascular Disease
(E)-Alprenoxime is the isomer of the Alprenoxime. Alprenoxime is a site-activated ocular β-blocker.

HY-17495A

Carteolol hydrochloride 2 Publications Verification OPC-1085 hydrochloride	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Carteolol hydrochloride (OPC-1085 hydrochloride) is a non-selective beta blocker used to treat glaucoma.

HY-N10497

Dihydro-β-erythroidine	nAChR	Neurological Disease
Dihydro-β-erythroidine is a a competitive nicotinic receptor antagonist. Dihydro-β-erythroidine blocks the discriminative stimulus properties of nicotine. Dihydro-β-erythroidine inhibits the anxiolytic effect of nicotine induced .

HY-100607A

Landiolol hydrochloride ONO1101 hydrochloride	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Landiolol hydrochloride (ONO1101 hydrochloride) is a highly beta1 selective ultra-short acting *beta*-blocker (β1/β2 selectivity = 255:1, a half-life of 4 min)， acts as an adrenoceptor antagonist .

HY-100607

Landiolol ONO1101	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Landiolol hydrochloride (ONO1101 hydrochloride) is a highly beta1 selective ultra-short acting beta-blocker (β1/β2 selectivity = 255:1, a half-life of 4 min), acts as an adrenoceptor antagonist .

HY-A0078

Mebeverine hydrochloride	Sodium Channel	Endocrinology
Mebeverine hydrochloride, a β-phenylethylamine derivative, is a musculotropic agent that potently blocks intestinal peristalsis. Mebeverine directly blocks voltage-operated sodium channels and inhibits intracellular calcium accumulation .

HY-118770

Nafetolol K 5407 free base	Adrenergic Receptor	Cardiovascular Disease
Nafetolol (K 5407), specifically effective on cardiac (β1)-adrenoceptors, is an orally active β blocking agent, with a t_1/2 of ~ 2 h in dogs .

HY-108302

Nifenalol	Adrenergic Receptor	Others
Nifenalol is a β-adrenergic receptor blocker. Nifenalol inhibits β-adrenoceptor differentiation in right atrium, diaphragm and adipose tissue in a rat model .

HY-B0437AS

Sotalol-d6 hydrochloride MJ 1999-d₆ hydrochloride	Adrenergic Receptor Potassium Channel	Cardiovascular Disease Endocrinology
Sotalol-d₆ (hydrochloride) is a deuterium labeled Sotalol hydrochloride. Sotalol hydrochloride is an orally active, non-selective competitive β-adrenergic receptor blocker. Sotalol hydrochloride is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol hydrochloride blocks β-receptors, and potassium KCNH2 channels[1][2].

HY-100635

Diacetolol	Drug Metabolite	Cardiovascular Disease Endocrinology
Diacetolol is an active metabolite of the beta-adrenoceptor blocking agent Acebutolol (HY-17497) .

HY-B0381

Betaxolol 4 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Betaxolol is a selective beta1 adrenergic receptor blocker that can be used for the research of hypertension and glaucoma.

HY-B0381A

Betaxolol hydrochloride 4 Publications Verification SL75212	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Betaxolol Hydrochloride is a selective beta1 adrenergic receptor blocker that can be used for the research of hypertension and glaucoma.

HY-105562

Nadoxolol	Adrenergic Receptor	Cardiovascular Disease
Nadoxolol is a non-selective β-adrenaline receptor blocker that can be used in the study of arrhythmias. .

HY-105154A

Proxodolol	Adrenergic Receptor	Cardiovascular Disease
Proxodolol is a β-adrenergic receptor blocker. Proxodolol can be used for the study of arterial hypertension .

HY-19495

OT-730	Others	Others
OT-730 is an innovative selective beta-blocker prodrug designed for research into ocular diseases.

HY-17498B

Atenolol hydrochloride (RS)-Atenolol hydrochloride; Tenormin hydrochloride; ICI 66082 hydrochloride	Adrenergic Receptor	Cardiovascular Disease Neurological Disease Endocrinology Cancer
Atenolol hydrochloride is a cardioselective β1-adrenergic receptor blocker, with a K_i of 697 nM at β1-adrenoceptor in guine pig left ventricle membrane. Atenolol hydrochloride can be used for the research of hypertension and angina pectoris .

HY-B0437S

Sotalol-d6 MJ 1999-d₆	Isotope-Labeled Compounds Adrenergic Receptor Potassium Channel	Cardiovascular Disease Neurological Disease
Sotalol-d₆ is the deuterium labeled Sotalol. Sotalol is an orally active, non-selective β-adrenergic receptor blocker. Sotalol is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent[1][2][3][4].

HY-118470

Butaxamine hydrochloride Butoxamin hydrochloride	Adrenergic Receptor	Endocrinology
Butaxamine (Butoxamin) hydrochloride is a specific β2-adrenergic receptor blocker. Butaxamine hydrochloride inhibits the decreases in urine volume in ethanol-anesthetized, water-diuretic rats .

HY-19022

BW A256C	Others	Cardiovascular Disease Others Metabolic Disease
Palatrigine is a compound with angiotensin-converting enzyme inhibitory and beta-adrenergic receptor blocking properties .

HY-17498

Atenolol 10+ Cited Publications (RS)-Atenolol	Adrenergic Receptor	Cardiovascular Disease Neurological Disease Endocrinology Cancer
Atenolol ((RS)-Atenolol) is a cardioselective β1-adrenergic receptor blocker, with a K_i of 697 nM at β1-adrenoceptor in guine pig left ventricle membrane. Atenolol can be used for the research of hypertension and angina pectoris .

HY-P5810

Ceratotoxin-2 CcoTx2; β-TRTX-cm1b	Sodium Channel	Neurological Disease
Ceratotoxin-2 (CcoTx2) is a voltage-gated sodium channel blocker with IC₅₀s of 8 nM and 88 nM against Na_v1.2/β₁ and Na_v1.3/β₁, respectively .

HY-P10634

P17 Peptide	TGF-beta/Smad	Others
P17 Peptide is a human TGF-β1 inhibitory peptide. P17 Peptide can block woodchuck TGF-β1 activity .

HY-129029

Bisoprolol 5+ Cited Publications	Adrenergic Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker with little activity on β2-receptor. Bisoprolol has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research .

Cat. No.	Product Name

HY-L145

Antihypertensive Compound Library

648 compounds

The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death.

Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs).

MCE offers a unique collection of 648 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

HY-L156

Autoimmune Disease Compound Library

531 compounds

Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A).

MCE designs a unique collection of 531 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

Cat. No.	Product Name	Type

HY-101461

Methyl-β-cyclodextrin 45+ Cited Publications Methyl-beta-cyclodextrin	Co-solvents
Methyl-β-cyclodextrin (Methyl-beta-cyclodextrin) is a cyclic heptasaccharide used to deliver hydrophobic agents based on its property of solubilizing non-polar substances. Methyl-β-cyclodextrin is also extensively used as a cholesterol-depleting reagent . Methyl-β-cyclodextrin strongly reduces clathrin-dependent endocytosis . Methyl-β-cyclodextrin blocks cell migrasome formation .

HY-W145552

4-Methoxyphenyl 3-O-allyl-β-D-galactopyranoside

4-Methoxyphenyl 3-O-allyl-beta-D-galactopyranoside

Carbohydrates

4-Methoxyphenyl 3-O-Allyl-β-D-galactopyranoside is an organic compound belonging to the family of galactopyranosides. It is often used as a building block for the synthesis of more complex glycosides and glycoconjugates. 4-Methoxyphenyl 3-O-Allyl-β-D-galactopyranoside has various applications in biochemical research, especially in the study of carbohydrate metabolism and protein-carbohydrate interactions. This compound contains an allyl protecting group that can be selectively removed using palladium-catalyzed conditions to reveal hydroxyl functionality for further chemical modification.

Cat. No.	Product Name	Target	Research Area

HY-P2565

Pepinh-TRIF TFA 4 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
Pepinh-TRIF (TFA) is a 30 aa peptide that blocks TIR-domain-containing adapter-inducing interferon-β (TRIF) signaling by interfering with TLR-TRIF interaction .

HY-P1264

α-Bungarotoxin 4 Publications Verification	nAChR	Neurological Disease
α-Bungarotoxin is a competitive antagonist at nicotinic acetylcholine receptors (nAChRs). α-Bungarotoxin, a selective α7 receptor blocker, blocks α7 currents with an IC₅₀ of 1.6 nM and has no effects on α3β4 currents at concentrations up to 3 μM .

HY-P5810

Ceratotoxin-2 CcoTx2; β-TRTX-cm1b	Sodium Channel	Neurological Disease
Ceratotoxin-2 (CcoTx2) is a voltage-gated sodium channel blocker with IC₅₀s of 8 nM and 88 nM against Na_v1.2/β₁ and Na_v1.3/β₁, respectively .

HY-P10634

P17 Peptide	TGF-beta/Smad	Others
P17 Peptide is a human TGF-β1 inhibitory peptide. P17 Peptide can block woodchuck TGF-β1 activity .

HY-P4886

Amyloid β-Protein (3-42)	Amyloid-β	Neurological Disease
Amyloid β-Protein (3-42) is the precursor of Pyr peptide. Pyroglutamate-modified Aβ (pEAβ) (3-42) is the core of the amyloid template block in Alzheimer's disease. pEAβ(3-42) accelerated the aggregation of Aβ(1-42), while Aβ(1-42) significantly slowed the primary and secondary nucleation of pEAβ(3-42) .

HY-P10414

Klotho-derived peptide 1 KP1 (human)	TGF-beta/Smad p38 MAPK	Inflammation/Immunology
Klotho-derived peptide 1 (KP1 human) blocks TGF-β/TGF-β receptor 2 interaction, inhibits TGF-β-induced activation of Smad2/3 and mitogen-activated protein kinase (MAPK), and exhibits anti-fibrotic and kidney protective effects in mouse model .

HY-P10414A

Klotho-derived peptide 1 hydrochloride KP1 (human) hydrochloride	TGF-beta/Smad p38 MAPK	Inflammation/Immunology
Klotho-derived peptide 1 (KP1 human) hydrochloride blocks TGF-β/TGF-β receptor 2 interaction, inhibits TGF-β-induced activation of Smad2/3 and mitogen-activated protein kinase (MAPK), and exhibits anti-fibrotic and kidney protective effects in mouse model .

HY-P10630

Pep63	Amyloid-β	Neurological Disease
Pep63 is a neuroprotective peptide (VFQVRARTVA). Pep63 has a neuroprotective effect on synaptic plasticity and memory. Pep63 can competitively bind with Aβ1-42 oligomers, and can block Aβ fiber formation. Pep63 can be used for Alzheimer’s disease (AD) research .

HY-P0118

Disitertide P144	TGF-beta/Smad PI3K Apoptosis	Cancer
Disitertide (P144) is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide (P144) is also a PI3K inhibitor and an apoptosis inducer .

HY-P0118A

Disitertide TFA P144 TFA	TGF-beta/Smad PI3K Apoptosis	Cancer
Disitertide (P144) TFA is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide TFA is also a PI3K inhibitor and an apoptosis inducer .

HY-P0118B

Disitertide diammonium Maximum Cited Publications 13 Publications Verification P144 diammonium	TGF-beta/Smad PI3K Apoptosis	Cancer
Disitertide (P144) diammonium is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide diammonium is also a PI3K inhibitor and an apoptosis inducer .

HY-P3971

H-Leu-Ser-Lys-Leu-OH	TGF-beta/Smad	Inflammation/Immunology
H-Leu-Ser-Lys-Leu-OH (LSYL) is a latency-associated peptide at the amino terminus of LAP, with inhibitory effect on *TGF-β1* activation. H-Leu-Ser-Lys-Leu-OH, binding with KRFK (HY-P3970), can block the signal transduction of *TGF-β1*, and prevent the progression of hepatic damage and fibrosis .

HY-P0109

(S,S)-Z-FA-FMK	Cathepsin	Others
(S,S)-Z-FA-FMK is a cell-permeable, irreversible cathepsin B inhibitor. (S,S)-Z-FA-FMK blocks LPS-induced production of IL-1α and IL-1β. (S,S)-Z-FA-FMK can be used as a negative control for caspase-1 and caspase-2 inhibitors because it lacks an aspartic acid residue at the P1 position .

HY-P10038

mP6 Myr-FEEERA-OH	Integrin	Infection
mP6 (Myr-FEEERA-OH) is a myristoylated peptide. mP6 inhibits the interaction of Gα₁₃ with integrin β₃ without disrupting talin-dependent integrin function. mP6 can block the GTP usage of Rac1, Rap1, and Rab7, effectively inhibiting the infection of CHO-A24 cells .

HY-P1682

Balixafortide POL6326	CXCR Arrestin	Cancer
Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC₅₀ < 10 nM. Balixafortide shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks *β-arrestin* recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

HY-P1847

IKKγ NBD Inhibitory Peptide	NF-κB	Cancer
IKKγ NBD Inhibitory Peptide is a highly specific inhibitor NF-κB inhibitor. IKKγ NBD Inhibitory Peptide acts by disrupting the interaction between IKKγ/NEMO-binding domain (NBD) with IKKα and IKKβ, thus blocking TNF-α-induced NF-kB activation. IKKγ NBD Inhibitory Peptide could significantly suppresses inflammation and ameliorate the cerebral ischemia-induced neurological deficits .

HY-P2141A

TRV-120027 TFA 3 Publications Verification	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027 TFA, a *β-arrestin-1*-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling . TRV120027 TFA induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the acute decompensated heart failure (ADHF) treatment .

HY-P2141

TRV-120027 3 Publications Verification	Angiotensin Receptor Arrestin	Cardiovascular Disease
TRV120027, a *β-arrestin-1*-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .

HY-P1682A

Balixafortide TFA 1 Publications Verification POL6326 TFA	CXCR Arrestin	Cancer
Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC₅₀ < 10 nM. Balixafortide TFA shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks *β-arrestin* recruitment and calcium flux with IC₅₀s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects .

HY-P1847A

IKKγ NBD Inhibitory Peptide TFA	NF-κB	Inflammation/Immunology
IKKγ NBD Inhibitory Peptide TFA is a highly specific inhibitor NF-κB inhibitor. IKKγ NBD Inhibitory Peptide TFA acts by disrupting the interaction between IKKγ/NEMO-binding domain (NBD) with IKKα and IKKβ, thus blocking TNF-α-induced NF-kB activation. IKKγ NBD Inhibitory Peptide TFA could significantly suppresses inflammation and ameliorate the cerebral ischemia-induced neurological deficits .

HY-P4190

Fsh receptor-binding inhibitor fragment(bi-10)	GnRH Receptor	Endocrinology
FSH receptor-binding inhibitor fragment(bi-10) is a potent FSH antagonist. FSH receptor-binding inhibitor fragment(bi-10) blocks the binding of FSH to FSHR, and alteres FSH action at the receptor level. FSH receptor-binding inhibitor fragment(bi-10) results in the suppression of ovulation and causes follicular atresia of mice. FSH receptor-binding inhibitor fragment(bi-10) has the potential for utilizing to restrain the carcinogenesis of ovarian cancer by down-regulating overexpression of FSHR and ERβ in the ovaries .

HY-W111226

Fmoc-His(3-Me)-OH	Amyloid-β Amino Acid Derivatives	Cardiovascular Disease
Fmoc-His(3-Me)OH derives Histidine-associating compounds with biological activity. Fmoc-His(3-Me)OH, with Fmoc-citrulline-OH, Fmoc-His(1-Me)-OH together, forms tri-peptides and shows vasodilating effect with EC₅₀s of 2.7-4.7 mM in 1.0 mM Phenylephrine (PE)-contracted aorta rings. Fmoc-His(3-Me)OH (resin) also makes Methyl-His-Gly-Lys (His(3-Me)-Gly-Lys), thus acts as an [Ca ²⁺]_i inhibitor. Fmoc-His(3-Me)OH methylates NAHIS02, making it unable to block the Alzheimer's Aβ channel .

Cat. No.	Product Name	Target	Research Area

HY-108831

Natalizumab 2 Publications Verification	Integrin	Inflammation/Immunology Cancer
Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .

HY-108831A

Natalizumab (Solution) 2 Publications Verification	Integrin	Inflammation/Immunology
Natalizumab (Solution) is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .

HY-P99379

Nidanilimab (Nadunolimab) CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)	Interleukin Related	Cancer
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a K_d value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2922

β-Amyrin	Structural Classification Monophenols Celastrus hindsii Benth. Celastraceae Phenols Plants	Amyloid-β
β-Amyrin, an ingredient of Celastrus hindsii, blocks amyloid β (Aβ)-induced long-term potentiation (LTP) impairment. β-amyrin is a promising candidate of treatment for AD .

HY-N0663

Talatisamine	Alkaloids Pyrrole Alkaloids Source classification Ranunculaceae Aconitum carmichaeli Debx. Plants	Potassium Channel
Talatisamine, a aconitum alkaloid, is specific K ⁺ channel blocker. Talatisamine attenuates beta-amyloid oligomers induced neurotoxicity in cultured cortical neurons .

HY-108831

Natalizumab 2 Publications Verification	Classification of Application Fields Disease Research Fields Cancer	Integrin
Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). Natalizumab can be used for the treatment of relapsing remitting multiple sclerosis and Crohn's disease. Natalizumab is also the first targeted therapy which blocks an essential mechanism for lymphocyte entry to the CNS and thus prevents acute demyelinating relapses .

HY-A0070A

Liothyronine 15+ Cited Publications Triiodothyronine; 3,3',5-Triiodo-L-thyronine; T3	Structural Classification Monophenols Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Phenols Endocrine diseases Endogenous metabolite Disease Research Fields Endocrinology	Thyroid Hormone Receptor Endogenous Metabolite
Liothyronine is an active form of thyroid hormone. Liothyronine binds to thyroid hormone receptors TRα and TRβ with K_is of 2.33 and 2.29 nM for hTRα and hTRβ, respectively. Liothyronine also binds to PVR and blocks the interaction of TIGIT/PVR .

HY-116753

(-)Clausenamide	Clausena lansium (Lour.) Skeels Source classification Rutaceae Plants	Amyloid-β Tau Protein
(-)Clausenamide is an active alkaloid isolated from the leaves of Clausena lansium (Lour.) Skeels, and improves cognitive function in both normal physiological and pathological conditions. (-)Clausenamide inhibits *β-amyloid* (Aβ) toxicity, blocking neurofibrillary tangle formation by inhibiting the phosphorylation of tau protein. (-)Clausenamide exerts a significant neuroprotective activity against Aβ_25-35. (-)Clausenamide can be used for researching Alzheimer's disease (AD) .

HY-N0001

(-)-Epicatechin 3 Publications Verification (-)-Epicatechol; Epicatechin; epi-Catechin	Structural Classification Classification of Application Fields Anti-aging Source classification Camellia sinensis (L.) O. Ktze. Plants Endogenous metabolite Flavonoids Sunscreen Flavanols Phenols Polyphenols Cosmetic Research Inflammation/Immunology Disease Research Fields Theaceae Cancer	COX Ferroptosis Endogenous Metabolite
(-)-Epicatechin inhibits cyclooxygenase-1 (COX-1) with an IC₅₀ of 3.2 μM. (-)-Epicatechin inhibits the IL-1β-induced expression of iNOS by blocking the nuclear localization of the p65 subunit of NF-κB.

HY-N2587

Irigenin	Structural Classification Flavonoids Iridaceae Classification of Application Fields Source classification Phenols Polyphenols Plants Belamcanda chinensis (Linn.) Redouté Disease Research Fields Isoflavones Cancer	Integrin Apoptosis
Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking *α9β1* and *α4β1* integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells .

HY-N10497

Dihydro-β-erythroidine	Alkaloids Leguminosae Plants	nAChR
Dihydro-β-erythroidine is a a competitive nicotinic receptor antagonist. Dihydro-β-erythroidine blocks the discriminative stimulus properties of nicotine. Dihydro-β-erythroidine inhibits the anxiolytic effect of nicotine induced .

HY-108306

Moprolol (±)-Moprolol	Cardiovascular Disease Classification of Application Fields Disease Research Fields	Adrenergic Receptor
Moprolol ((±)-Moprolol) is an beta-adrenergic receptor blocker, which can be used for research in essential hypertension .

HY-N2513R

β-Boswellic acid (Standard)	Structural Classification other families Classification of Application Fields Terpenoids Source classification Boswellia serrata Plants Burseraceae Disease Research Fields Cancer	Lipoxygenase DNA/RNA Synthesis
β-Boswellic acid (Standard) is the analytical standard of β-Boswellic acid. This product is intended for research and analytical applications. β-Boswellic acid is isolated from the gum resin of Boswellia serrata. β-Boswellic acid is a nonreducing-type inhibitor of the 5-lipoxygenase (5-LO) product formation either interacting directly with the 5-LO or blocking its translocation . β-Boswellic acid inhibits the synthesis of DNA, RNA and protein in human leukemia HL-60 cells .

HY-B1494

Picrotoxinin 3 Publications Verification	Structural Classification Natural Products other families Source classification Plants	Chloride Channel GABA Receptor
Picrotoxinin, a potent convulsant, is a chloride channel blocker. Picrotoxinin is a noncompetitive GABA_A receptor antagonist, which negatively modulates the action of GABA on GABA_A receptors. Picrotoxinin inhibits α₁β₂γ_2L GABA_A receptor with an IC₅₀ of 1.15 μM .

HY-N2513

β-Boswellic acid	Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Source classification Boswellia serrata Plants Burseraceae Disease Research Fields Cancer	Lipoxygenase DNA/RNA Synthesis
β-Boswellic acid is isolated from the gum resin of Boswellia serrata with anticancer, antioxidant activity, anti-inflammatory activity and anti-arthritic pain.β-Boswellic acid is an orally active nonreducing-type inhibitor of the 5-lipoxygenase (5-LO) product formation either interacting directly with the 5-LO or blocking its translocation. β-Boswellic acid inhibits the synthesis of DNA, RNA and protein in human leukemia HL-60 cells with IC₅₀ values ranging from 0.6 to 7.1 μM. β-Boswellic acid is promising for research of diabetes, inflammatory and arthritic diseases .

HY-N2587R

Irigenin (Standard)	Structural Classification Flavonoids Iridaceae Source classification Phenols Polyphenols Plants Belamcanda chinensis (Linn.) Redouté Isoflavones	Integrin Apoptosis
Irigenin (Standard) is the analytical standard of Irigenin. This product is intended for research and analytical applications. Irigenin is a is a lead compound, and mediates its anti-metastatic effect by specifically and selectively blocking α9β1 and α4β1 integrins binding sites on C-C loop of Extra Domain A (EDA). Irigenin shows anti-cancer properties. It sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells .

HY-N0001R

(-)-Epicatechin (Standard) (-)-Epicatechol(Standard); Epicatechin(Standard); epi-Catechin (Standard)	Structural Classification Classification of Application Fields Anti-aging Source classification Plants Camellia sinensis (L.) O. Ktze. Endogenous metabolite Flavonoids Sunscreen Phenols Cosmetic Research Inflammation/Immunology Disease Research Fields Cancer Theaceae	COX Ferroptosis Endogenous Metabolite
(-)-Epicatechin (Standard) is the analytical standard of (-)-Epicatechin. This product is intended for research and analytical applications. (-)-Epicatechin inhibits cyclooxygenase-1 (COX-1) with an IC₅₀ of 3.2 μM. (-)-Epicatechin inhibits the IL-1β-induced expression of iNOS by blocking the nuclear localization of the p65 subunit of NF-κB.

HY-W008859

Tetrac 1 Publications Verification Tetraiodothyroacetic acid; 3,3',5,5'-Tetraiodothyroacetic acid	Structural Classification Monophenols Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Endogenous metabolite Disease Research Fields Cancer	Integrin Endogenous Metabolite
Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities .

HY-B1494R

Picrotoxinin (Standard)	Structural Classification Natural Products other families Source classification Plants	Chloride Channel GABA Receptor
Picrotoxinin (Standard) is the analytical standard of Picrotoxinin. This product is intended for research and analytical applications. Picrotoxinin, a potent convulsant, is a chloride channel blocker. Picrotoxinin is a noncompetitive GABAA receptor antagonist, which negatively modulates the action of GABA on GABAA receptors. Picrotoxinin inhibits α1β2γ2L GABAA receptor with an IC₅₀ of 1.15 μM .

HY-14393

Emodin Maximum Cited Publications 21 Publications Verification Frangula emodin	Structural Classification Classification of Application Fields Polygonaceae Source classification Plants Endogenous metabolite Quinones Human Gut Microbiota Metabolites Microorganisms Rheum palmatum L. Anthraquinones Phenols Polyphenols Disease Research Fields Cancer	SARS-CoV Casein Kinase Autophagy 11β-HSD
Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction . Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects . Emodin is a potent selective *11β-HSD1* inhibitor with the IC₅₀ of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice .

HY-121197

Balanol Ophiocordin; Azepinostatin	Structural Classification Natural Products Microorganisms Source classification	MARCKS PKA PKC
Balanol (Ophiocordin; Azepinostatin) is a potent and ATP competitive PKC/PKA inhibitor against human PKC isozymes α, β-I, β-II, γ, δ, ε, η (IC₅₀s=4-9 nM) and ζ (IC₅₀=150 nM). Balanol also blocks the phosphorylation of cyclic AMP response element-binding protein (CREB) and myristoylated alanine-rich C kinase substrate (MARCKS). Balanol can be isolated from the fungus Verticillium balanoides .

HY-P99379

Nidanilimab (Nadunolimab) CAN04; Anti-IL-1RAP/IL-1R3 Reference Antibody (nidanilimab)	Classification of Application Fields Disease Research Fields Cancer	Interleukin Related
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a K_d value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) .

HY-14393R

Emodin (Standard) Frangula emodin (Standard)	Quinones Structural Classification Rheum palmatum L. Classification of Application Fields Polygonaceae Source classification Phenols Plants Disease Research Fields Cancer	SARS-CoV Casein Kinase Autophagy 11β-HSD
Emodin (Standard) is the analytical standard of Emodin. This product is intended for research and analytical applications. Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction . Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects . Emodin is a potent selective *11β-HSD1* inhibitor with the IC₅₀ of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice .

HY-N6064

Polygalacin D 1 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Source classification Platycodon grandiflorus (Jacq.) A. DC. Campanulaceae Plants Disease Research Fields Cancer	Apoptosis IAP
Polygalacin D (PGD) is a bioactive compound isolated from Platycodon grandiflorum with anticancer and anti-proliferative properties. PGD suppresses the expression of the IAP family of proteins including survivin, cIAP-1 and cIAP-2 and blocks the PI3K/Akt pathway by inhibiting the phosphorylation of GSK3β, Akt and the expression of PI3K. Polygalacin D induces apoptosis

HY-N1584

Halofuginone 10+ Cited Publications RU-19110	Infection Cardiovascular Disease Alkaloids Piperidine Alkaloids Structural Classification Classification of Application Fields Dichroa febrifuga Lour Source classification Saxifragaceae Plants Inflammation/Immunology Disease Research Fields	DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel
Halofuginone (RU-19110), a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a K_i of 18.3 nM . Halofuginone is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of *TGF-β* activity . Halofuginone is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca ²⁺ channels. Halofuginone has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .

HY-N2278

Kushenol A 1 Publications Verification Leachianone E	Structural Classification Flavonoids Classification of Application Fields Leguminosae Flavonones Source classification Phenols Polyphenols Sophora flavescens Aiton Plants Disease Research Fields Cancer	Tyrosinase Glucosidase
Kushenol A (Leachianone E) is isolated from the root of Sophora flavescent. Kushenol A is a non-competitive tyrosinase inhibitor to block the conversion of L-tyrosine to L-DOPA, shows IC₅₀ and K_ivalues of 1.1 μM and 0.4 μM, respectively . Kushenol A is a flavonoid antioxidant, has inhibitory effects on alpha-glucosidase (IC₅₀: 45 μM; K_i: 6.8 μM) and β-amylase . Kushenol A is confirmed as potential inhibitors of enzymes targeted by cosmetics for skin whitening and aging .

HY-N1584A

Halofuginone hydrobromide 10+ Cited Publications RU-19110 hydrobromide	Infection Cardiovascular Disease Alkaloids Piperidine Alkaloids Structural Classification Classification of Application Fields Dichroa febrifuga Lour Source classification Saxifragaceae Plants Inflammation/Immunology Disease Research Fields	DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel
Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a K_i of 18.3 nM . Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of *TGF-β* activity . Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca ²⁺ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .

HY-N2503

Ginsenoside F4	Panax ginseng C. A. Meyer Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Plants Inflammation/Immunology Disease Research Fields Araliaceae	Apoptosis MMP
Ginsenoside F4 (GF4), ginseng saponinis, isolated from notoginseng or red ginseng. Ginsenoside F4 (GF4) has inhibitory effect on human lymphocytoma JK cell by inducing its apoptosis . Ginsenoside F4 (GF4) inhibits matrix metalloproteinase 13 (MMP 13) expression in IL-1β-treated chondrocytes and blocks cartilage breakdown in rabbit cartilage tissue culture, shows therapeutic potential for preventing cartilage collagen matrix breakdown in diseased tissues .

HY-N1584AR

Halofuginone hydrobromide (Standard)	Alkaloids Piperidine Alkaloids Structural Classification Dichroa febrifuga Lour Source classification Saxifragaceae Plants	DNA/RNA Synthesis TGF-beta/Smad Parasite Sodium Channel Calcium Channel
Halofuginone (hydrobromide) (Standard) is the analytical standard of Halofuginone (hydrobromide). This product is intended for research and analytical applications. Halofuginone (RU-19110) hydrobromid, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a K_i of 18.3 nM . Halofuginone hydrobromid is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of *TGF-β* activity . Halofuginone hydrobromid is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca ²⁺ channels. Halofuginone hydrobromid has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects .

HY-W017113

2-Mercaptobenzothiazole	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite Aryl Hydrocarbon Receptor
2-Mercaptobenzothiazole is an activator of the aryl hydrocarbon receptor (AhR) , inhibiting thyroid hormone synthesis and dopamine beta-hydroxylase activity . 2-Mercaptobenzothiazole promotes bladder cancer cell invasion by altering the conformation of the AhR ligand binding domain (LBD), activating AhR transcription, and upregulating the mRNA and protein expression of target genes CYP1A1 and CYP1B1 . 2-Mercaptobenzothiazole inhibits thyroid peroxidase (TPO) with an IC₅₀ value of 11.5 μM, induces histological changes such as follicular cell hypertrophy in Xenopus laevis tadpoles, delaying metamorphosis . 2-Mercaptobenzothiazole increases chromosomal aberrations and sister chromatid exchanges (SCEs) in Chinese hamster ovary (CHO) cells, and enhances carcinogenicity in F344/N rats . 2-Mercaptobenzothiazole inhibits norepinephrine synthesis in mice and completely blocks the conversion of exogenous dopamine to norepinephrine in rat cardiomyocytes .

Cat. No.	Product Name	Chemical Structure

HY-B0804S

Nadolol-d9
Nadolol-d₉ is the deuterium labeled Nadolol. Nadolol is a non-selective and orally active β-adrenergic receptors blocker[1].

HY-B0437AS

Sotalol-d6 hydrochloride
Sotalol-d₆ (hydrochloride) is a deuterium labeled Sotalol hydrochloride. Sotalol hydrochloride is an orally active, non-selective competitive β-adrenergic receptor blocker. Sotalol hydrochloride is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol hydrochloride blocks β-receptors, and potassium KCNH2 channels[1][2].

HY-17498S

Atenolol-d7
Atenolol-d₇ is the deuterium labeled Atenolol. Atenolol ((RS)-Atenolol) is a cardioselective β1-adrenergic receptor blocker, with a Ki of 697 nM atβ1-adrenoceptor in guine pig left ventricle membrane. Atenolol can be used for the research of hypertension and angina pectoris[1][2].

HY-B1392S

Esmolol-d7 hydrochloride
Esmolol-d₇ (hydrochloride) is the deuterium labeled Esmolol hydrochloride. Esmolol hydrochloride is a beta adrenergic receptor blocker[1][2].

HY-B0437S

Sotalol-d6
Sotalol-d₆ is the deuterium labeled Sotalol. Sotalol is an orally active, non-selective β-adrenergic receptor blocker. Sotalol is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent[1][2][3][4].

HY-129029S

Bisoprolol-d5
Bisoprolol-d₅ is the deuterium labeled Bisoprolol. Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research[1][2].

HY-B0076S

Bisoprolol-d7 hemifumarate
Bisoprolol-d₇ (hemifumarate) is the deuterium labeled Bisoprolol hemifumarate. Bisoprolol hemifumarate is a selective type β1 adrenergic receptor blocker.

HY-B0381S

Betaxolol-d5
Betaxolol-d₅ is the deuterium labeled Betaxolol. Betaxolol is a selective beta1 adrenergic receptor blocker that can be used for the research of hypertension and glaucoma.

HY-B0381AS

Betaxolol-d7 hydrochloride
Betaxolol-d₇ (hydrochloride) is the deuterium labeled Betaxolol hydrochloride. Betaxolol Hydrochloride is a selective beta1 adrenergic receptor blocker that can be used for the research of hypertension and glaucoma.

HY-17495AS

Carteolol-d9 hydrochloride
Carteolol-d₉ (hydrochloride) is the deuterium labeled Carteolol hydrochloride. Carteolol hydrochloride (OPC-1085 hydrochloride) is a non-selective beta blocker used to treat glaucoma[1][2].

HY-100635S

Diacetolol-d7
Diacetolol-d₇ is a deuterium labeled Diacetolol. Diacetolol is the major metabolite of Acebutolol. Diacetolol is a β-adrenoceptor blocking and anti-arrhythmic agent[1].

HY-17503S

Metoprolol-d7
Metoprolol-d₇ is the deuterium labeled Metoprolol. Metoprolol (Toprol) is a selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension[1][2].

HY-17503S2

(S)-Metoprolol-d7
(S)-Metoprolol-d₇ is the deuterium labeled Metoprolol. Metoprolol (Toprol) is a selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension[1][2].

HY-17503S1

(R)-Metoprolol-d7
(R)-Metoprolol-d₇ is the deuterium labeled Metoprolol. Metoprolol (Toprol) is a selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension[1][2].

HY-108286S

(Rac)-Talinolol-d5
(Rac)-Talinolol-d₅ is the racemate of Talinolol. Talinolol (Cordanum) is a long-acting, cardioselective β1-adrenergic receptor blocker. Talinolol exhibits cardioprotective and antihypertensive activities. Talinolol is also a well-known and frequently used probe substrate for P-glycoprotein (P-gp) activity[1][2][3].

HY-B0753S

Gliclazide-d4
Gliclazide-d₄ (S1702 D4) is the deuterium labeled Gliclazide. Gliclazide (S1702) is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 nM. Gliclazide is used as an antidiabetic[1].

HY-B0006S

Carvedilol-d3
Carvedilol-d₃ is the deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective β/α-1 blocker[1]. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure[2]. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome[3].

HY-B0006S1

Carvedilol-d4
Carvedilol-d₄ is the deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective β/α-1 blocker[1]. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure[2]. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome[3].

HY-B0006S2

Carvedilol-d5
Carvedilol-d₅ is deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective β/α-1 blocker[1]. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure[2]. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome[3].

HY-B0982S

Pindolol-d7
Pindolol-d₇ (LB-46-d7) is the deuterium labeled Pindolol. Pindolol (LB-46) is a nonselective β-blocker with partial beta-adrenergic receptor agonist activity, also functions as a 5-HT1A receptor weak partial antagonist (Ki=33 nM)[1][2].

HY-B0006BS

(S)-Carvedilol-d4
(S)-Carvedilol-d₄ is deuterium labeled (S)-Carvedilol. (S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)[1].

HY-B0006CS

(R)-Carvedilol-d4
(R)-Carvedilol-d₄ is deuterium labeled (R)-Carvedilol. (R)-Carvedilol ((R)-BM 14190), the R-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (R)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)[1].

HY-10019S1

Varenicline-15N,13C,d2

Varenicline- ¹⁵N, ¹³C,d₂ is ¹⁵N and deuterated labeled Varenicline (HY-10019). Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀=250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-10020S

Varenicline-15N3 hydrochloride

Varenicline-15N3 Hydrochloride (CP 526555-15N3 Hydrochloride) is the ¹⁵N labeled isotope of Varenicline hydrochloride (HY-10020). Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-N0001S

(±)-Epicatechin-13C3
(±)-Epicatechin- ¹³C₃ is the ¹³C labeled (±)-Epicatechin. (-)-Epicatechin (HY-N0001) inhibits cyclooxygenase-1 (COX-1) with an IC50 of 3.2 μM. (-)-Epicatechin inhibits the IL-1β-induced expression of iNOS by blocking the nuclear localization of the p65 subunit of NF-κB[1].

HY-B0254S

Glipizide-d11
Glipizide-d₁₁ is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (KATP) channels among β cells of pancreatic islets of Langerhans[1][2].

HY-17494S

(Rac)-Timolol-d5 maleate

rac Timolol-d₅ (maleate) is a labelled racemic (S)-Timolol maleate. (S)-Timolol Maleate (L-714,465 Maleate) is a non-cardioselective hydrophilic β-adrenoceptor blocker. (S)-Timolol Maleate is widely used as standard medication for intraocular pressure (glaucoma) by preventing the production of aqueous humor. (S)-Timolol Maleate can be used for hypertension, angina pectoris and myocardial infarction[1][2][3].

HY-17380S

(S)-Timolol-d9 maleate

(S)-Timolol-d₉ (maleate) is deuterium labeled (S)-Timolol (Maleate). (S)-Timolol Maleate (L-714,465 Maleate) is a non-cardioselective hydrophilic β-adrenoceptor blocker. (S)-Timolol Maleate is widely used as standard medication for intraocular pressure (glaucoma) by preventing the production of aqueous humor. (S)-Timolol Maleate can be used for hypertension, angina pectoris and myocardial infarction[1][2][3].

HY-14393S

Emodin-d4

Emodin-d₄ is the deuterium labeled Emodin. Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction[1]. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects[2]. Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice[3].

HY-A0016S

Dronedarone D6 hydrochloride

Dronedarone-d₆ (hydrochloride) is the deuterium labeled Dronedarone. Dronedarone hydrochloride, a derivative of Amiodarone (HY-14187), is a class III antiarrhythmic agent for the study of atrial fibrillation (AF) and atrial flutter. Dronedarone hydrochloride is a potent blocker of multiple ion currents, including potassium current, sodium current, and L-type calcium current, and exhibits antiadrenergic effects by noncompetitive binding to β-adrenergic receptors. Dronedarone hydrochloride is a substrate for and a moderate inhibitor of CYP3A4[1][2][3][4].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks